董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Susannah Gray | 女 | Independent Director | 66 | 28.75万美元 | 8.08 | 2025-10-27 |
| Luke Marker | 男 | Director | 41 | 25.25万美元 | 4.89 | 2025-10-27 |
| Sean L. Cunningham | 男 | Director | 51 | 26.00万美元 | 4.89 | 2025-10-27 |
| Constantine S. Mihas | 男 | Director | 59 | 26.25万美元 | 4.89 | 2025-10-27 |
| Bernd Brust | -- | Director and Chief Executive Officer | -- | 1012.97万美元 | 未持股 | 2025-10-27 |
| Robert Andrew Eckert | -- | Chairman of the Board | -- | 67.50万美元 | 未持股 | 2025-10-27 |
| John A. DeFord | -- | Independent Director | -- | 28.50万美元 | 4.88 | 2025-10-27 |
| Gregory T. Lucier | 男 | Independent Director | 61 | 25.25万美元 | 7.58 | 2025-10-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Christine Dolan | 女 | Executive Vice President and General Manager, Cygnus Technologies | 58 | 145.42万美元 | 未持股 | 2025-10-27 |
| Kevin Herde | 男 | Principal Accounting Officer | 55 | 173.07万美元 | 29.68 | 2025-10-27 |
| Kurt Oreshack | 男 | General Counsel and Secretary | 46 | 147.10万美元 | 未持股 | 2025-10-27 |
| Bernd Brust | -- | Director and Chief Executive Officer | -- | 1012.97万美元 | 未持股 | 2025-10-27 |
| Rajesh J. Asarpota | -- | Chief Financial Officer | -- | 350.68万美元 | 未持股 | 2025-10-27 |
董事简历
中英对照 | 中文 | 英文- Susannah Gray
-
Susannah Gray自2020年7月起担任我们的董事会成员。Gray女士曾于2005年至2019年担任Royalty Pharma Management，LLC财务和战略执行Vice President，该公司是药品特许权使用费的购买者和整个生物制药行业的供资者，并担任其他各种类似职务。在加入Royalty Pharma之前，Gray女士从2002年到2004年担任CIBS世界市场高收益集团梦百合部门的董事总经理和高级分析师，此前还在摩根大通证券公司的前身美林证券公司和大通证券公司担任过类似职务。Gray女士目前在Susan G.Komen的董事会任职，并在卫斯理大学（Wesleyan University）的董事会任职。Gray女士于1982年在卫斯理大学（Wesleyan University）获得文学学士学位，并于1990年在哥伦比亚大学（Columbia University）获得工商管理硕士学位。
Susannah Gray has served as a member of board of directors since July 2020. Ms. Gray served as the Executive Vice President of Finance and Strategy of Royalty Pharma Management, LLC, a buyer of pharmaceutical royalties and a funder across the biopharmaceutical industry, and in various other similar roles from 2005 until 2019. Prior to Royalty Pharma, Ms. Gray served as a managing director and senior analyst covering the healthcare sector of CIBS World Market's high yield group from 2002 to 2004 and also previously served in similar roles at Merrill Lynch and Chase Securities, Inc. predecessor of JP Morgan Securities, Inc.. Ms. Gray currently serves on the board of directors of Susan G. Komen and serves on the Board of Trustees of Wesleyan University. Ms. Gray received a B.A. from Wesleyan University in 1982 and an M.B.A. from Columbia University in 1990. - Susannah Gray自2020年7月起担任我们的董事会成员。Gray女士曾于2005年至2019年担任Royalty Pharma Management，LLC财务和战略执行Vice President，该公司是药品特许权使用费的购买者和整个生物制药行业的供资者，并担任其他各种类似职务。在加入Royalty Pharma之前，Gray女士从2002年到2004年担任CIBS世界市场高收益集团梦百合部门的董事总经理和高级分析师，此前还在摩根大通证券公司的前身美林证券公司和大通证券公司担任过类似职务。Gray女士目前在Susan G.Komen的董事会任职，并在卫斯理大学（Wesleyan University）的董事会任职。Gray女士于1982年在卫斯理大学（Wesleyan University）获得文学学士学位，并于1990年在哥伦比亚大学（Columbia University）获得工商管理硕士学位。
- Susannah Gray has served as a member of board of directors since July 2020. Ms. Gray served as the Executive Vice President of Finance and Strategy of Royalty Pharma Management, LLC, a buyer of pharmaceutical royalties and a funder across the biopharmaceutical industry, and in various other similar roles from 2005 until 2019. Prior to Royalty Pharma, Ms. Gray served as a managing director and senior analyst covering the healthcare sector of CIBS World Market's high yield group from 2002 to 2004 and also previously served in similar roles at Merrill Lynch and Chase Securities, Inc. predecessor of JP Morgan Securities, Inc.. Ms. Gray currently serves on the board of directors of Susan G. Komen and serves on the Board of Trustees of Wesleyan University. Ms. Gray received a B.A. from Wesleyan University in 1982 and an M.B.A. from Columbia University in 1990.
- Luke Marker
-
Luke Marker将在本次发行完成后开始在我们的董事会任职，并自2016年以来一直担任MLSH1’；s董事会成员。Mark先生于2009年加入GTCR，并于2020年成为负责人。加入GTCR公司之前，他曾任职Lehman Brothers公司、Barclays Capital公司的投资银行部门。Marker先生持有Harvard Business School的荣誉工商管理硕士学位和Kalamazoo College的数学和经济学学士学位。Mark先生曾在MLSH1的管理委员会任职，并将继续任职，直到他被任命为与发行完成有关的董事。
Luke Marker will begin serving on board upon the completion of this offering and has served as a member of MLSH 1's board since 2016. Mr. Marker joined GTCR in 2009 and became a Principal in 2020. Prior to joining GTCR, he worked in the investment banking division at Lehman Brothers and Barclays Capital. Mr. Marker holds an MBA with distinction from Harvard Business School and a BA in Mathematics and Economics from Kalamazoo College. Mr. Marker served on the board of managers of MLSH 1 and will continue to serve until he is appointed as director in connection with the closing of the offering. - Luke Marker将在本次发行完成后开始在我们的董事会任职，并自2016年以来一直担任MLSH1’；s董事会成员。Mark先生于2009年加入GTCR，并于2020年成为负责人。加入GTCR公司之前，他曾任职Lehman Brothers公司、Barclays Capital公司的投资银行部门。Marker先生持有Harvard Business School的荣誉工商管理硕士学位和Kalamazoo College的数学和经济学学士学位。Mark先生曾在MLSH1的管理委员会任职，并将继续任职，直到他被任命为与发行完成有关的董事。
- Luke Marker will begin serving on board upon the completion of this offering and has served as a member of MLSH 1's board since 2016. Mr. Marker joined GTCR in 2009 and became a Principal in 2020. Prior to joining GTCR, he worked in the investment banking division at Lehman Brothers and Barclays Capital. Mr. Marker holds an MBA with distinction from Harvard Business School and a BA in Mathematics and Economics from Kalamazoo College. Mr. Marker served on the board of managers of MLSH 1 and will continue to serve until he is appointed as director in connection with the closing of the offering.
- Sean L. Cunningham
-
Sean L.Cunningham自2020年10月起担任我们的董事会成员，自2015年起担任Topco Parent&8217；的董事会成员。Cunningham先生于2001年加入GTCR，目前是该公司的常务董事。加入GTCR公司之前，他曾担任The Boston Consulting Group的顾问。Cunningham先生目前是几家私人公司的董事。他持有Dartmouth College的工程科学A.B.和B.E.学位，以及宾夕法尼亚大学沃顿商学院（the Wharton School at the University of Pennsylvania）的工商管理硕士学位。
Sean L. Cunningham has served as a member of board of directors since October 2020 and as a member of Topco Parent's board of managers since 2015. Mr. Cunningham joined GTCR in 2001 and is currently a managing director of the firm. Prior to joining GTCR, he worked as a consultant with The Boston Consulting Group. Mr. Cunningham currently is a director of several private companies. He holds A.B. and B.E. degrees in engineering sciences from Dartmouth College and an M.B.A. from the Wharton School at the University of Pennsylvania. - Sean L.Cunningham自2020年10月起担任我们的董事会成员，自2015年起担任Topco Parent&8217；的董事会成员。Cunningham先生于2001年加入GTCR，目前是该公司的常务董事。加入GTCR公司之前，他曾担任The Boston Consulting Group的顾问。Cunningham先生目前是几家私人公司的董事。他持有Dartmouth College的工程科学A.B.和B.E.学位，以及宾夕法尼亚大学沃顿商学院（the Wharton School at the University of Pennsylvania）的工商管理硕士学位。
- Sean L. Cunningham has served as a member of board of directors since October 2020 and as a member of Topco Parent's board of managers since 2015. Mr. Cunningham joined GTCR in 2001 and is currently a managing director of the firm. Prior to joining GTCR, he worked as a consultant with The Boston Consulting Group. Mr. Cunningham currently is a director of several private companies. He holds A.B. and B.E. degrees in engineering sciences from Dartmouth College and an M.B.A. from the Wharton School at the University of Pennsylvania.
- Constantine S. Mihas
-
Constantine S.Mihas自2020年10月起担任我们的董事会成员，自2015年起担任Topco Parent&8217；的董事会成员。Mihas先生于2001年加入GTCR，目前是该公司的董事总经理。在加入GTCR之前，Mihas先生是Delray Farms（一家专业食品零售商）的首席执行官兼联合创始人。任职Delray Farms公司之前，他曾任职McKinsey&Company。Mihas先生领导着GTCR的梦百合集团，并在建立该公司在生命科学和医疗设备方面的专业知识方面发挥了重要作用。他目前是几家私人公司的董事。Mihas先生在伊利诺伊大学芝加哥分校（University of Illinois，Chicago）获得金融和经济学学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
Constantine S. Mihas has served as a member of board of directors since October 2020 and as a member of Topco Parent's board of managers since 2015. Mr. Mihas joined GTCR in 2001 and is currently a managing director of the firm. Prior to joining GTCR, Mr. Mihas was chief executive officer and co-founder of Delray Farms, a specialty food retailer. Prior to Delray Farms, he was with McKinsey & Company. Mr. Mihas leads the Healthcare group at GTCR and has been instrumental in building the firm's expertise in life sciences and medical devices. He is currently a director of several private companies. Mr. Mihas holds a B.S. with high distinction in finance and economics from the University of Illinois, Chicago and an M.B.A. with distinction from the Harvard Business School. - Constantine S.Mihas自2020年10月起担任我们的董事会成员，自2015年起担任Topco Parent&8217；的董事会成员。Mihas先生于2001年加入GTCR，目前是该公司的董事总经理。在加入GTCR之前，Mihas先生是Delray Farms（一家专业食品零售商）的首席执行官兼联合创始人。任职Delray Farms公司之前，他曾任职McKinsey&Company。Mihas先生领导着GTCR的梦百合集团，并在建立该公司在生命科学和医疗设备方面的专业知识方面发挥了重要作用。他目前是几家私人公司的董事。Mihas先生在伊利诺伊大学芝加哥分校（University of Illinois，Chicago）获得金融和经济学学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
- Constantine S. Mihas has served as a member of board of directors since October 2020 and as a member of Topco Parent's board of managers since 2015. Mr. Mihas joined GTCR in 2001 and is currently a managing director of the firm. Prior to joining GTCR, Mr. Mihas was chief executive officer and co-founder of Delray Farms, a specialty food retailer. Prior to Delray Farms, he was with McKinsey & Company. Mr. Mihas leads the Healthcare group at GTCR and has been instrumental in building the firm's expertise in life sciences and medical devices. He is currently a director of several private companies. Mr. Mihas holds a B.S. with high distinction in finance and economics from the University of Illinois, Chicago and an M.B.A. with distinction from the Harvard Business School.
- Bernd Brust
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Robert Andrew Eckert
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- John A. DeFord
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Gregory T. Lucier
-
Gregory T. Lucier，他一直担任董事会成员（2015年4月以来）。Lucier先生是Corza Health， Inc.（自2019年4月以来专注于收购医疗保健公司和资产的公司）的首席执行官。在此之前，他曾担任NuVasive， Inc.（医疗器械公司）的董事长兼首席执行官（2015年至2018年）。加入NuVasive之前，Lucier先生从2003年5月起担任Life Technologies Corporation（一家全球生物技术公司）的董事长兼首席执行官，直到该公司于2014年2月被Thermo Fisher Scientific Inc.收购。在此之前，Lucier先生是通用电气公司的公司官员，在那里他担任各种领导职务。Lucier先生是Dentsply Sirona的董事长和Maravai LifeSciences的董事。此前，他曾担任Life Technologies Corporation（2003年5月至2014年2月）、Carefusion Corporation（2009年8月至2015年3月出售给Becton Dickinson）、Invuity, inc（2014年10月至2018年10月出售给Stryker）和Nuvasive（2013年12月至2021年5月）的董事。他持有Harvard Business School的工商管理硕士学位和Pennsylvania State大学的工业工程学士学位。
Gregory T. Lucier,has been a member of the Board since April 2015. Mr. Lucier is the chief executive officer of Corza Health, Inc. a company focused on acquiring healthcare companies and assets since April 2019. Prior to that, he served as Chairman and Chief Executive Officer of NuVasive, Inc., a medical device company, from 2015 to 2018. Before joining NuVasive, Mr. Lucier was Chairman and Chief Executive Officer of Life Technologies Corporation, a global biotechnology company, from May 2003 until it was acquired by Thermo Fisher Scientific Inc. in February 2014. Prior to that, Mr. Lucier was a corporate officer at General Electric Company, where he served in a variety of leadership roles. Mr. Lucier is chairman of Dentsply Sirona and a director at Maravai LifeSciences. He previously served as a director of Life Technologies Corporation from May 2003 to February 2014, of Carefusion Corporation from August 2009 until its sale to Becton Dickinson in March 2015, of Invuity, Inc. from October 2014 until its sale to Stryker in October 2018, and of Nuvasive from December 2013 to May 2021. Mr. Lucier received an M.B.A. from Harvard Business School and a B.S. in industrial engineering from Pennsylvania State University. - Gregory T. Lucier，他一直担任董事会成员（2015年4月以来）。Lucier先生是Corza Health， Inc.（自2019年4月以来专注于收购医疗保健公司和资产的公司）的首席执行官。在此之前，他曾担任NuVasive， Inc.（医疗器械公司）的董事长兼首席执行官（2015年至2018年）。加入NuVasive之前，Lucier先生从2003年5月起担任Life Technologies Corporation（一家全球生物技术公司）的董事长兼首席执行官，直到该公司于2014年2月被Thermo Fisher Scientific Inc.收购。在此之前，Lucier先生是通用电气公司的公司官员，在那里他担任各种领导职务。Lucier先生是Dentsply Sirona的董事长和Maravai LifeSciences的董事。此前，他曾担任Life Technologies Corporation（2003年5月至2014年2月）、Carefusion Corporation（2009年8月至2015年3月出售给Becton Dickinson）、Invuity, inc（2014年10月至2018年10月出售给Stryker）和Nuvasive（2013年12月至2021年5月）的董事。他持有Harvard Business School的工商管理硕士学位和Pennsylvania State大学的工业工程学士学位。
- Gregory T. Lucier,has been a member of the Board since April 2015. Mr. Lucier is the chief executive officer of Corza Health, Inc. a company focused on acquiring healthcare companies and assets since April 2019. Prior to that, he served as Chairman and Chief Executive Officer of NuVasive, Inc., a medical device company, from 2015 to 2018. Before joining NuVasive, Mr. Lucier was Chairman and Chief Executive Officer of Life Technologies Corporation, a global biotechnology company, from May 2003 until it was acquired by Thermo Fisher Scientific Inc. in February 2014. Prior to that, Mr. Lucier was a corporate officer at General Electric Company, where he served in a variety of leadership roles. Mr. Lucier is chairman of Dentsply Sirona and a director at Maravai LifeSciences. He previously served as a director of Life Technologies Corporation from May 2003 to February 2014, of Carefusion Corporation from August 2009 until its sale to Becton Dickinson in March 2015, of Invuity, Inc. from October 2014 until its sale to Stryker in October 2018, and of Nuvasive from December 2013 to May 2021. Mr. Lucier received an M.B.A. from Harvard Business School and a B.S. in industrial engineering from Pennsylvania State University.
高管简历
中英对照 | 中文 | 英文- Christine Dolan
Christine Dolan，她曾担任Maravai Lifesciences Holdings, Inc.的首席运营官。自2017年10月起担任生物制品安全检测业务部门。加入Maravai之前，Dolan女士是Catalent, Inc.的产品开发高级副总裁。“Catalent”是一家生物技术公司，Dolan女士在那里工作了8年多。加入Catalent之前，Dolan女士曾担任GE Healthcare（医疗技术公司）的核运营和全球质量控制总监以及QC、验证和供应链管理总监3年多。加入GE Healthcare之前，Dolan女士在Amersham担任QC和材料管理总监，在那里她工作了十多年。Dolan女士持有Lenoir-Rhyne College的生物学学士学位。
Christine Dolan has served as the Chief Operating Officer of Maravai Lifesciences Holdings, Inc. Biologics Safety Testing business segment since October 2017. Prior to joining Maravai, Ms. Dolan was a Senior Vice President of Product Development at Catalent, Inc. "Catalent", a biotechnology company, where Ms. Dolan worked for over eight years. Prior to joining Catalent, Ms. Dolan was a Director of Nuclear Operations and Global Quality Control and a Director of QC, Validation and Supply Chain Management at GE Healthcare, a medical technology company, for over three years. Prior to joining GE Healthcare, Ms. Dolan was a Director of QC and Materials Management at Amersham, where she worked for over ten years. Ms. Dolan holds a BS in Biology from Lenoir-Rhyne College.- Christine Dolan，她曾担任Maravai Lifesciences Holdings, Inc.的首席运营官。自2017年10月起担任生物制品安全检测业务部门。加入Maravai之前，Dolan女士是Catalent, Inc.的产品开发高级副总裁。“Catalent”是一家生物技术公司，Dolan女士在那里工作了8年多。加入Catalent之前，Dolan女士曾担任GE Healthcare（医疗技术公司）的核运营和全球质量控制总监以及QC、验证和供应链管理总监3年多。加入GE Healthcare之前，Dolan女士在Amersham担任QC和材料管理总监，在那里她工作了十多年。Dolan女士持有Lenoir-Rhyne College的生物学学士学位。
- Christine Dolan has served as the Chief Operating Officer of Maravai Lifesciences Holdings, Inc. Biologics Safety Testing business segment since October 2017. Prior to joining Maravai, Ms. Dolan was a Senior Vice President of Product Development at Catalent, Inc. "Catalent", a biotechnology company, where Ms. Dolan worked for over eight years. Prior to joining Catalent, Ms. Dolan was a Director of Nuclear Operations and Global Quality Control and a Director of QC, Validation and Supply Chain Management at GE Healthcare, a medical technology company, for over three years. Prior to joining GE Healthcare, Ms. Dolan was a Director of QC and Materials Management at Amersham, where she worked for over ten years. Ms. Dolan holds a BS in Biology from Lenoir-Rhyne College.
- Kevin Herde
Kevin Herde自2017年5月起担任我们的首席财务官。在加入Maravai之前，他曾于2016年4月至2017年5月担任生物制药公司索伦托医疗公司的执行Vice President兼首席财务官，并于2015年1月至2016年2月担任Hologic的全球血液筛查Vice President。在Gen-Probe于2012年被Hologic收购之前，Herde先生还曾担任Gen-Probe的Vice President、财务和公司财务总监。Herde先生在毕马威会计师事务所（KPMG LLC）开始了他的职业生涯。Herde先生拥有圣地亚哥大学（University of San Diego）工商管理学士学位，是加利福尼亚州一名不活跃的注册会计师。
Kevin Herde has served as Chief Financial Officer since May 2017. Prior to joining Maravai, he served as Executive Vice President and Chief Financial Officer at Sorrento Therapeutics, Inc., a biopharmaceutical company, from April 2016 to May 2017 and as Vice President of Global Blood Screening at Hologic from January 2015 to February 2016. Mr. Herde also served as Vice President, Finance and Corporate Controller at Gen-Probe prior to its acquisition by Hologic in 2012. Mr. Herde began his career at KPMG LLC. Mr. Herde holds a BBA in Business Administration from University of San Diego and is a certified public accountant in California inactive.- Kevin Herde自2017年5月起担任我们的首席财务官。在加入Maravai之前，他曾于2016年4月至2017年5月担任生物制药公司索伦托医疗公司的执行Vice President兼首席财务官，并于2015年1月至2016年2月担任Hologic的全球血液筛查Vice President。在Gen-Probe于2012年被Hologic收购之前，Herde先生还曾担任Gen-Probe的Vice President、财务和公司财务总监。Herde先生在毕马威会计师事务所（KPMG LLC）开始了他的职业生涯。Herde先生拥有圣地亚哥大学（University of San Diego）工商管理学士学位，是加利福尼亚州一名不活跃的注册会计师。
- Kevin Herde has served as Chief Financial Officer since May 2017. Prior to joining Maravai, he served as Executive Vice President and Chief Financial Officer at Sorrento Therapeutics, Inc., a biopharmaceutical company, from April 2016 to May 2017 and as Vice President of Global Blood Screening at Hologic from January 2015 to February 2016. Mr. Herde also served as Vice President, Finance and Corporate Controller at Gen-Probe prior to its acquisition by Hologic in 2012. Mr. Herde began his career at KPMG LLC. Mr. Herde holds a BBA in Business Administration from University of San Diego and is a certified public accountant in California inactive.
- Kurt Oreshack
Kurt Oreshack自2020年11月起担任我们的总法律顾问。在加入Maravai之前，Oreshack先生是Breakwater Law Group，LLP律师事务所的合伙人，在公司法和证券法领域执业。在加入Breakwater Law Group之前，Oreshack先生于2015年6月至2017年9月担任基因组研究和体外诊断公司Human Longevity，Inc.的总法律顾问。离开Human Longevity后，Oreshack先生单独执业，并在Gunderson Dettmer Stough Villeneuve Franklin&Hachigian，LLP律师事务所担任常驻总法律顾问，直到2019年1月加入Breakwater Law Group。Oreshack先生在圣母大学法学院（University of Notre Dame Law School）获得法学博士学位，在芝加哥洛约拉大学（Loyola University Chicago）获得文学学士学位。他是the State Bar of California的成员。
Kurt Oreshack has served as General Counsel since November 2020. Prior to joining Maravai, Mr. Oreshack was a partner in the law firm of Breakwater Law Group, LLP, practicing in the field of corporate and securities law. Prior to joining Breakwater Law Group, Mr. Oreshack was the General Counsel of Human Longevity, Inc., a genomic research and in vitro diagnostics company, from June 2015 through September 2017. After leaving Human Longevity, Mr. Oreshack practiced law individually and as General Counsel in Residence at the law firm of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP until joining Breakwater Law Group in January 2019. Mr. Oreshack received a JD from the University of Notre Dame Law School and a BA from Loyola University Chicago. He is a member of the State Bar of California.- Kurt Oreshack自2020年11月起担任我们的总法律顾问。在加入Maravai之前，Oreshack先生是Breakwater Law Group，LLP律师事务所的合伙人，在公司法和证券法领域执业。在加入Breakwater Law Group之前，Oreshack先生于2015年6月至2017年9月担任基因组研究和体外诊断公司Human Longevity，Inc.的总法律顾问。离开Human Longevity后，Oreshack先生单独执业，并在Gunderson Dettmer Stough Villeneuve Franklin&Hachigian，LLP律师事务所担任常驻总法律顾问，直到2019年1月加入Breakwater Law Group。Oreshack先生在圣母大学法学院（University of Notre Dame Law School）获得法学博士学位，在芝加哥洛约拉大学（Loyola University Chicago）获得文学学士学位。他是the State Bar of California的成员。
- Kurt Oreshack has served as General Counsel since November 2020. Prior to joining Maravai, Mr. Oreshack was a partner in the law firm of Breakwater Law Group, LLP, practicing in the field of corporate and securities law. Prior to joining Breakwater Law Group, Mr. Oreshack was the General Counsel of Human Longevity, Inc., a genomic research and in vitro diagnostics company, from June 2015 through September 2017. After leaving Human Longevity, Mr. Oreshack practiced law individually and as General Counsel in Residence at the law firm of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP until joining Breakwater Law Group in January 2019. Mr. Oreshack received a JD from the University of Notre Dame Law School and a BA from Loyola University Chicago. He is a member of the State Bar of California.
- Bernd Brust
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Rajesh J. Asarpota
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介